Findings

What do systematic reviews say?

99 questions · 101 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 37 · 36.6%GRADE not reported 6 · 5.9%Very low 16 · 15.8%Low 18 · 17.8%Moderate 24 · 23.8%High 0 · 0%

Foam sclerotherapy vs placebo

Cosmetic appearance · participants with varicose veinsa

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 223 participants
Very low

Foam sclerotherapy vs placebo

Complications ‐ DVT · participants with varicose veinsa

It is very uncertain whether foam sclerotherapy changes complications ‐ DVT compared with placebo (very low certainty).

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
RR 5.1 [1.3, 20.01]
3 studies · 302 participants
Very low

Foam sclerotherapy vs placebo

Residual varicose veins · participants with varicose veinsa

It is very uncertain whether foam sclerotherapy changes residual varicose veins compared with placebo (very low certainty).

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
RR 0.19 [0.13, 0.29]
2 studies · 225 participants
Very low

Foam sclerotherapy vs placebo

QoL · participants with varicose veinsa

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 299 participants
Very low

Foam sclerotherapy vs placebo

Persistence of symptoms · participants with varicose veinsa

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 223 participants
Low

Foam sclerotherapy vs placebo

Recurrent varicose veins · participants with varicose veinsa

The review found no eligible studies for this question.

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 710 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.35, 1.99]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.21, 3.28]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy may leads to higher pain ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 2.44 [1.69, 3.55]
1 study · 596 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.82 [0.52, 1.27]
7 studies · 859 participants
Moderate

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 480 participants
Moderate

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 852 participants
Moderate

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.94 [0.62, 1.43]
6 studies · 819 participants
Moderate